FDA slammed for perpetuating “confusion and gray area” in CBD supplement regulation
The US food and drug agency holds its ground that risks run too high to allow the ingredient to be openly marketed
The US food and drug agency holds its ground that risks run too high to allow the ingredient to be openly marketed